心力衰竭誘發慢加急性肝衰竭臨床分析一例_West China Medical Journal

Authors：

 凌學斌 ^1,2 , 陳立宇 ¹ ,  馮萍 ¹

1. ;
2. ;

Corresponding?author：

馮萍, Email: fengp_62@163.com

Keywords：

心力衰竭; 肝衰竭; 托伐普坦; 利尿

DOI：

10.7507/1002-0179.20150055

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 凌學斌, 陳立宇, 馮萍. 心力衰竭誘發慢加急性肝衰竭臨床分析一例. West China Medical Journal, 2015, 30(1): 183-184. doi: 10.7507/1002-0179.20150055 Copy

1.	?中華醫學會感染病學分會肝衰竭與人工肝學組和中華醫學會肝病學分會重型肝病與人工肝學組.肝衰竭診療指南[J].藥品評價, 2007, 14(1):3-7.
2.	Yu JW, Wang GQ, Li SC. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system[J]. J Gastroenterol Hepatol, 2006, 21(10):1519-1524.
3.	趙振剛, 韓濤, 高英堂, 等.乙型肝炎患者并發慢加急性肝衰竭誘因及轉歸分析289例[J].世界華人消化雜志, 2009, 17(31):3269-3272.
4.	陳墾, 伍靈達, 崔淑蘭.心源性肝硬化[J].臨床薈萃, 1993, 8(17/18):782-784.
5.	Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics:a phaseⅢ, randomized, double-blind, placebo-controlled study (QUEST study)[J]. Cardiovasc Drugs Ther, 2011, 25(Suppl 1):S33-S45.
6.	Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20):2099-2112.
7.	Kinugawa K, Ohtani T. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure[J]. Int Heart J, 2014, 55(3):264-267.
8.	Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population[J]. J Cardiol, 2013, 61(1/2):169-174.
9.	Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2012, 367(25):2407-2418.
10.	Plosker GL. Tolvaptan[J]. Drugs, 2010, 70(4):443-454.

1. ?中華醫學會感染病學分會肝衰竭與人工肝學組和中華醫學會肝病學分會重型肝病與人工肝學組.肝衰竭診療指南[J].藥品評價, 2007, 14(1):3-7.
2. Yu JW, Wang GQ, Li SC. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system[J]. J Gastroenterol Hepatol, 2006, 21(10):1519-1524.
3. 趙振剛, 韓濤, 高英堂, 等.乙型肝炎患者并發慢加急性肝衰竭誘因及轉歸分析289例[J].世界華人消化雜志, 2009, 17(31):3269-3272.
4. 陳墾, 伍靈達, 崔淑蘭.心源性肝硬化[J].臨床薈萃, 1993, 8(17/18):782-784.
5. Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics:a phaseⅢ, randomized, double-blind, placebo-controlled study (QUEST study)[J]. Cardiovasc Drugs Ther, 2011, 25(Suppl 1):S33-S45.
6. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20):2099-2112.
7. Kinugawa K, Ohtani T. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure[J]. Int Heart J, 2014, 55(3):264-267.
8. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population[J]. J Cardiol, 2013, 61(1/2):169-174.
9. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2012, 367(25):2407-2418.
10. Plosker GL. Tolvaptan[J]. Drugs, 2010, 70(4):443-454.

West China Medical Journal

心力衰竭誘發慢加急性肝衰竭臨床分析一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content